Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Crucell and DSM Biologics Announce Additional PER.C6(R) Licensing Agreement with MorphoSys
- Leiden, The Netherlands, 17 March 2008 - Dutch biotechnology company Crucell N.V. and DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced that German-based MorphoSys AG has decided to extend the PER.C6® technology licensing agreement entered in September 2004, ...
- Research articles 2008-03-17
- DSM Biologics and Crucell Announce PER.C6(R) Licensing Agreement with Daiichi Sankyo Ltd.
- Sittard/Leiden, The Netherlands, November 16, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a PER.C6® license agreement with Daiichi Sankyo Ltd. (Tokyo Stock Exchange Ticker 4568). This license agreement allows Daiichi Sankyo...
- Research articles 2007-11-16
- DSM Biologics and Crucell Announce PER.C6(R) Licensing Deal With LFB Biotechnologies
- Sittard/Leiden, The Netherlands, July 25, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Paris, France-based LFB Biotechnologies. LFB Biotechnologies will use Crucell's technology...
- Research articles 2007-07-25
- Crucell and DSM Biologics announce PER.C6(R) license agreement with AbGenomics Corporation
- PRESS RELEASE Crucell and DSM Biologics announce PER.C6® license agreement with AbGenomics Corporation Sittard/Leiden, The Netherlands, 11 January 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics today announced that they have signed a PER.C6® research license agreement with...
- Research articles 2007-01-11
- MorphoSys Obtains PER.C6(R) Human Cell Line for Production of Antibody Material in MOR103 Program
- MorphoSys AG (FRANKFURT: MOR) (Prime Standard Segment, TecDAX) today announced the signing of a second PER.C6® license agreement with Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (NASDAQ: CRXL) and contract manufacturer DSM Biologics. This license agreement allows MorphoSys to use the PER.C6® cell line in the production of clinical grade...
- Research articles 2006-08-17
- Crucell and DSM Biologics Announce PER.C6(R) Licensing Agreement with UCB
- Leiden/Sittard, The Netherlands, March 14, 2006 - Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with global biopharmaceutical leader...
- Research articles 2006-03-14
- Crucell and DSM further strengthen and expand the development of PER.C6(R) Protein and Monoclonal Antibody Licensing Business
- Leiden/Heerlen, The Netherlands, December 20, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and DSM Biologics, a business unit of DSM Pharmaceutical Products a business group of Royal DSM NV announced today that they will...
- Research articles 2005-12-20
- Crucell and DSM further strengthen and expand the development of PER.C6(R) Protein and Monoclonal Antibody Licensing Business
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and DSM Biologics, a business unit of DSM Pharmaceutical Products a business group of Royal DSM NV announced today that they will strengthen and expand the development of the PER.C6® protein and monoclonal antibody licensing business. The two companies will create an...
- Research articles 2005-12-20
- Crucell/Dsm Sign Licensing Pact With Mitsubishi Pharma
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) has announced that allied contract manufacturer DSM Biologics has signed a PER.C6 research license agreement with the Japanese pharmaceutical company Mitsubishi Pharma Corporation. This license agreement allows Mitsubishi to use the PER.C6 cell line for production of certain recombinant therapeutic proteins. This...
- Research articles 2005-05-01
- Crucell Licenses Per.C6 Technology To Glaxosmithkline
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics have announced that Crucell has signed a PER.C6 research license agreement with GlaxoSmithKline. This license allows GlaxoSmithKline to use Crucell's PER.C6 technology in research and preclinical development related to its portfolio of recombinant monoclonal antibody products....
- Research articles 2004-10-01
- << Previous
- page 1 of 1
- Next >>
